肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

妊娠期和产后分化型甲状腺癌促甲状腺激素抑制治疗中国专家共识（2019版）

2020-03-15 中国医师协会外科医师分会 中国实用外科杂志.2020,40(3):255-259.

甲状腺癌促甲状腺激素

分化型甲状腺癌（differentiated thyroid cancer，DTC）是近年来发病率增加最快的实体肿瘤之一，也是育龄期女性最常见的内分泌系统恶性肿瘤。促甲状腺激素（thyrotropin

中文标题：

妊娠期和产后分化型甲状腺癌促甲状腺激素抑制治疗中国专家共识（2019版）

发布机构：

中国医师协会外科医师分会

发布日期：

2020-03-15

简要介绍：

分化型甲状腺癌（differentiated thyroid cancer，DTC）是近年来发病率增加最快的实体肿瘤之一，也是育龄期女性最常见的内分泌系统恶性肿瘤。促甲状腺激素（thyrotropin，TSH）抑制治疗是DTC术后管理的重要一环。随着对优生优育的重视和国家计划生育政策的调整，育龄期女性DTC病人在妊娠期和产后阶段其TSH抑制治疗的相关问题日益受到关注。本共识针对这一特殊人群、特殊时期的TSH 抑制治疗。

相关资料下载：
[AttachmentFileName(sort=1, fileName=)] GetToolGuiderByIdResponse(projectId=1, id=8fffc1c00188a87a, title=妊娠期和产后分化型甲状腺癌促甲状腺激素抑制治疗中国专家共识（2019版）, enTitle=, guiderFrom=中国实用外科杂志.2020,40(3):255-259., authorId=0, author=, summary=分化型甲状腺癌（differentiated thyroid cancer，DTC）是近年来发病率增加最快的实体肿瘤之一，也是育龄期女性最常见的内分泌系统恶性肿瘤。促甲状腺激素（thyrotropin, cover=https://img.medsci.cn/2020328/1585398998182_2020535.jpg, journalId=0, articlesId=null, associationId=737, associationName=中国医师协会外科医师分会, associationIntro=null, copyright=0, guiderPublishedTime=Sun Mar 15 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>分化型甲状腺癌（differentiated thyroid cancer，DTC）是近年来发病率增加最快的实体肿瘤之一，也是育龄期女性最常见的内分泌系统恶性肿瘤。促甲状腺激素（thyrotropin，TSH）抑制治疗是DTC术后管理的重要一环。随着对优生优育的重视和国家计划生育政策的调整，育龄期女性DTC病人在妊娠期和产后阶段其TSH抑制治疗的相关问题日益受到关注。本共识针对这一特殊人群、特殊时期的TSH 抑制治疗。</p> </div> </div> </div>, tagList=[TagDto(tagId=865, tagName=甲状腺癌), TagDto(tagId=8517, tagName=促甲状腺激素)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=23, categoryName=普通外科, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=865, guiderKeyword=甲状腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2803, appHits=290, showAppHits=23, pcHits=784, showPcHits=2581, likes=2, shares=16, comments=19, approvalStatus=1, publishedTime=Sat Mar 28 20:38:11 CST 2020, publishedTimeString=2020-03-15, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat Mar 28 20:36:51 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 01:04:53 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=)])
下载请点击：
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2102784, encodeId=a90d2102e8460, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sat Nov 26 18:10:27 CST 2022, time=2022-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208055, encodeId=93cf120805586, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sat Apr 02 08:46:33 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189520, encodeId=2e8e11895200b, content=学习，学习，再学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Tue Feb 01 01:46:04 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067850, encodeId=b962106e8504f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:52:13 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011307, encodeId=cef2101130ed3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40042504744, createdName=124a83fem50暂无昵称, createdTime=Wed Aug 25 11:56:56 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
    2022-11-26 1471d48dm72暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2102784, encodeId=a90d2102e8460, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sat Nov 26 18:10:27 CST 2022, time=2022-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208055, encodeId=93cf120805586, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sat Apr 02 08:46:33 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189520, encodeId=2e8e11895200b, content=学习，学习，再学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Tue Feb 01 01:46:04 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067850, encodeId=b962106e8504f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:52:13 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011307, encodeId=cef2101130ed3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40042504744, createdName=124a83fem50暂无昵称, createdTime=Wed Aug 25 11:56:56 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
    2022-04-02 1471d48dm72暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2102784, encodeId=a90d2102e8460, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sat Nov 26 18:10:27 CST 2022, time=2022-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208055, encodeId=93cf120805586, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sat Apr 02 08:46:33 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189520, encodeId=2e8e11895200b, content=学习，学习，再学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Tue Feb 01 01:46:04 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067850, encodeId=b962106e8504f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:52:13 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011307, encodeId=cef2101130ed3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40042504744, createdName=124a83fem50暂无昵称, createdTime=Wed Aug 25 11:56:56 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
    2022-02-01 1de15b39m16(暂无匿称)

    学习，学习，再学习！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2102784, encodeId=a90d2102e8460, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sat Nov 26 18:10:27 CST 2022, time=2022-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208055, encodeId=93cf120805586, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sat Apr 02 08:46:33 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189520, encodeId=2e8e11895200b, content=学习，学习，再学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Tue Feb 01 01:46:04 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067850, encodeId=b962106e8504f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:52:13 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011307, encodeId=cef2101130ed3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40042504744, createdName=124a83fem50暂无昵称, createdTime=Wed Aug 25 11:56:56 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
    2021-11-07 1471d48dm72暂无昵称

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2102784, encodeId=a90d2102e8460, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sat Nov 26 18:10:27 CST 2022, time=2022-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208055, encodeId=93cf120805586, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sat Apr 02 08:46:33 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189520, encodeId=2e8e11895200b, content=学习，学习，再学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Tue Feb 01 01:46:04 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067850, encodeId=b962106e8504f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:52:13 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011307, encodeId=cef2101130ed3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40042504744, createdName=124a83fem50暂无昵称, createdTime=Wed Aug 25 11:56:56 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
    2021-08-25 124a83fem50暂无昵称

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2019 专家共识：乐伐替尼治疗甲状腺癌期间不良事件的管理

国外肿瘤科相关专家小组（统称） · 2019-12-13

2019 ESMO临床实践指南：甲状腺癌的诊断，治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2019-09-24

2018 CSCO临床指南：持续/复发及转移性分化型甲状腺癌的诊断和治疗（英文版）

中国临床肿瘤学会(CSCO,Chinese Society of Clinical Oncology) · 2019-02-20

甲状腺癌诊疗规范（2018年版）

中华人民共和国国家卫生健康委员会 · 2018-12-13

2018 波兰国家指南：甲状腺癌的诊断和治疗（更新版）

国外肿瘤科相关专家小组（统称） · 2018-08-20

拓展阅读

2009 ATA 甲状腺结节和分化型甲状腺癌指南修订版

美国甲状腺协会(ATA,American Thyroid Association) · 2009-12-01

分化型甲状腺癌诊治指南

中国抗癌协会头颈肿瘤外科专业委员会 · 2010-10-01

2012 ESMO临床实践指南：甲状腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2012中国甲状腺结节和分化型甲状腺癌指南

中华医学会内分泌学分会(CSE,Chinese Society of Endocrinology) · 2012-08-08

2012ATA 未分化甲状腺癌管理指南

美国甲状腺协会(ATA,American Thyroid Association) · 2012-11-06

2013 ETA颈部超声扫描和超声引导技术在甲状腺癌患者术后管理中的应用指南

欧洲甲状腺协会(ETA,European Thyroid Association) · 2013-09-05